What is a stock summary page? Click here for an overview.
Business Description
Krystal Biotech Inc
NAICS : 325412
SIC : 2836
ISIN : US5011471027
Compare
Compare
Traded in other countries / regions
KRYS.USA4KB.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2017-09-20Description
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 82.29 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 30.1 | |||||
| Beneish M-Score | 1.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Book Growth Rate | 11.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 52.35 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 42.06 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.71 | |||||
| 9-Day RSI | 49.36 | |||||
| 14-Day RSI | 53.3 | |||||
| 3-1 Month Momentum % | 12.53 | |||||
| 6-1 Month Momentum % | 1.19 | |||||
| 12-1 Month Momentum % | 0.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.28 | |||||
| Quick Ratio | 7.02 | |||||
| Cash Ratio | 5.86 | |||||
| Days Inventory | 273.97 | |||||
| Days Sales Outstanding | 98.95 | |||||
| Days Payable | 92.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.5 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.1 | |||||
| Operating Margin % | 35.52 | |||||
| Net Margin % | 30.69 | |||||
| FCF Margin % | 41.02 | |||||
| ROE % | 10.49 | |||||
| ROA % | 9.63 | |||||
| ROIC % | 32.45 | |||||
| 3-Year ROIIC % | 94.26 | |||||
| ROC (Joel Greenblatt) % | 51.6 | |||||
| ROCE % | 12.05 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 61.51 | |||||
| Forward PE Ratio | 25.89 | |||||
| PE Ratio without NRI | 44.66 | |||||
| Price-to-Owner-Earnings | 108.06 | |||||
| PS Ratio | 18.84 | |||||
| PB Ratio | 5.6 | |||||
| Price-to-Tangible-Book | 5.6 | |||||
| Price-to-Free-Cash-Flow | 46.1 | |||||
| Price-to-Operating-Cash-Flow | 44.5 | |||||
| EV-to-EBIT | 45.62 | |||||
| EV-to-Forward-EBIT | 22.16 | |||||
| EV-to-EBITDA | 42.83 | |||||
| EV-to-Forward-EBITDA | 22.16 | |||||
| EV-to-Revenue | 16.2 | |||||
| EV-to-Forward-Revenue | 10.51 | |||||
| EV-to-FCF | 39.5 | |||||
| Price-to-Projected-FCF | 20.53 | |||||
| Price-to-Graham-Number | 3.33 | |||||
| Price-to-Net-Current-Asset-Value | 8.37 | |||||
| Price-to-Net-Cash | 10.85 | |||||
| Earnings Yield (Greenblatt) % | 2.19 | |||||
| FCF Yield % | 2.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KRYS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Krystal Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 290.514 | ||
| EPS (TTM) ($) | 2.99 | ||
| Beta | 0.75 | ||
| 3-Year Sharpe Ratio | 0.89 | ||
| 3-Year Sortino Ratio | 2.01 | ||
| Volatility % | 41.99 | ||
| 14-Day RSI | 53.3 | ||
| 14-Day ATR ($) | 7.336109 | ||
| 20-Day SMA ($) | 183.52925 | ||
| 12-1 Month Momentum % | 0.74 | ||
| 52-Week Range ($) | 141.72 - 219.34 | ||
| Shares Outstanding (Mil) | 28.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Krystal Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Krystal Biotech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Krystal Biotech Inc Frequently Asked Questions
What is Krystal Biotech Inc(KRYS)'s stock price today?
The current price of KRYS is $183.92. The 52 week high of KRYS is $219.34 and 52 week low is $141.72.
When is next earnings date of Krystal Biotech Inc(KRYS)?
The next earnings date of Krystal Biotech Inc(KRYS) is 2025-05-06 Est..
Does Krystal Biotech Inc(KRYS) pay dividends? If so, how much?
Krystal Biotech Inc(KRYS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers